Cargando…

Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

BACKGROUND: Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually decrease the severity of the symptoms by 20–30%; however, 40–60% of OCD patients do not achieve a satisfactory response. Our main objective was to investigate the effectiveness of memantine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Askari, Sanaz, Mokhtari, Saba, Shariat, Seyed Vahid, Shariati, Behnam, Yarahmadi, Masoomeh, Shalbafan, Mohammadreza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753835/ https://www.ncbi.nlm.nih.gov/pubmed/35022014 http://dx.doi.org/10.1186/s12888-021-03642-z

Ejemplares similares

Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial
por: Shokrani, Marjan, et al.
Publicado: (2023)

Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial
por: Ghobadian, Ala, et al.
Publicado: (2022)

Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial
por: Askari, S.
Publicado: (2023)

Raphe nuclei echogenicity changes in obsessive-compulsive disorder
por: Mohammadzade, Nahid, et al.
Publicado: (2018)

The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial
por: Mahdavi, Seyed Mani, et al.
Publicado: (2022)

An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
por: Bakhla, Ajay Kumar, et al.
Publicado: (2013)

Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
por: Hadi, Fatemeh, et al.
Publicado: (2021)

Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder
por: Shahini, Najmeh, et al.
Publicado: (2021)

Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline
por: Lissemore, Jennifer I., et al.
Publicado: (2018)

Executive Functioning in Chinese Patients With Obsessive Compulsive Disorder
por: Ren, Huicong, et al.
Publicado: (2021)

Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
por: Thamby, Abel, et al.
Publicado: (2019)

Glutamatergic augmentation strategies in obsessive–compulsive disorder
por: Sheshachala, Karthik, et al.
Publicado: (2019)

The story of memory and executive functions in obsessive-compulsive disorder: a case-control study
por: Hamidian, Sajedeh, et al.
Publicado: (2022)

Executive Functioning and Clinical Variables in Patients with Obsessive-Compulsive Disorder
por: Martínez-Esparza, Inmaculada Concepción, et al.
Publicado: (2021)

Executive Functions and Reinforcement Sensitivity in Women with Obsessive Compulsive Symptoms
por: Amani, Malahat, et al.
Publicado: (2022)

Safety and Efficacy of Drug Holidays for Women with Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) Other than Fluoxetine: An Open-Label Randomized Clinical Trial
por: Lalegani, Elham, et al.
Publicado: (2023)

Effect of sertraline and fluvoxamine on quality of life in patients with obsessive–compulsive disorder: A 12-week interventional study
por: Brar, Jasmine, et al.
Publicado: (2022)

Neuropsychological Functioning in Obsessive-Compulsive Washers: Drug-Naive Without Depressive Symptoms
por: Saremi, Ali Akbar, et al.
Publicado: (2017)

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
por: Maraone, Annalisa, et al.
Publicado: (2023)

Neural Correlates of Executive Functioning in Anorexia Nervosa and Obsessive–Compulsive Disorder
por: Thomas, Kai S., et al.
Publicado: (2022)

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia
por: Eryılmaz, Gül, et al.
Publicado: (2013)

Working in the emergency and inpatient COVID-19 special wards: A different experience for Iranian psychiatric trainees amid the outbreak
por: Shariati, Behnam, et al.
Publicado: (2020)

Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials
por: Eissazade, Negin, et al.
Publicado: (2023)

A Computational Approach for the Assessment of Executive Functions in Patients with Obsessive–Compulsive Disorder
por: Pedroli, Elisa, et al.
Publicado: (2019)

Prevalence of Obsessive-Compulsive Spectrum Disorders in Obsessive-Compulsive Disorder
por: Siddiqui, Mohammad Aleem, et al.
Publicado: (2018)

Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder
por: Amerio, Andrea, et al.
Publicado: (2018)

Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder
por: Di Salvo, Gabriele, et al.
Publicado: (2020)

Transformation obsessions in Obsessive-Compulsive Disorder
por: Sharma, Pooja, et al.
Publicado: (2022)

Transformation obsessions in Obsessive-Compulsive Disorder
por: Sharma, Pooja, et al.
Publicado: (2022)

Perceived Stress in Obsessive–Compulsive Disorder is Related with Obsessive but Not Compulsive Symptoms
por: Morgado, P., et al.
Publicado: (2013)

Attitude of Iranian medical specialty trainees toward providing health care services to patients with mental disorders
por: Movahedi, Sana, et al.
Publicado: (2022)

Virtual reality exposure and response prevention in the treatment of obsessive-compulsive disorder in patients with contamination subtype in comparison with in vivo exposure therapy: a randomized clinical controlled trial
por: Javaherirenani, Razieh, et al.
Publicado: (2022)

Divergent subcortical activity for distinct executive functions: stopping and shifting in obsessive compulsive disorder
por: Morein-Zamir, S., et al.
Publicado: (2016)

Executive Functioning Constructs in Anxiety, Obsessive–Compulsive, Post-Traumatic Stress, and Related Disorders
por: Zainal, Nur Hani, et al.
Publicado: (2022)

Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy
por: Skarphedinsson, Gudmundur, et al.
Publicado: (2015)

Memantine as an Augmentation Therapy for Anxiety Disorders
por: Schwartz, Thomas L., et al.
Publicado: (2012)

Relationship between severity of obsessive-compulsive symptoms and schizotypy in obsessive-compulsive disorder
por: Yamamoto, Haruka, et al.
Publicado: (2012)

Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study
por: Delle Chiaie, Roberto, et al.
Publicado: (2011)

Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report
por: Fornaro, Michele, et al.
Publicado: (2008)

Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors
por: Signorelli, Maria S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qcg6l2hi4ur8to66ddoeo7aat6